Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis

Pharmacogenetics and Genomics

Volumn 18, Issue 3, 2008, Pages 253-262

  Shukla, Sunita J ^a   Duan, Shiwei ^a   Badner, Judith A ^a   Wu, Xiaolin ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apoptosis; Association; Centre d'Etude du Polymorphisme Humain; Cisplatin; Cytotoxicity; Heritability; Linkage

Indexed keywords

CISPLATIN;

APOPTOSIS; ARTICLE; CELL BASED GENE THERAPY; CELL GROWTH; CHEMOTHERAPY; CHROMOSOME; CONFIDENCE INTERVAL; CYTOTOXICITY; GENE LOCUS; GENETIC LINKAGE; GENETIC VARIABILITY; GROWTH INHIBITION; HEREDITY; HERITABILITY; HUMAN; LINKAGE ANALYSIS; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE (GENETICS); LYMPHOCYTES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS);

EID: 40049084479     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282f5e605     Document Type: Article

References (52)

1. Ho YP, Au-Yeung SC, To KK. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 2003; 23:633-655.
2. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1:227-235.
3. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573-584.
4. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005; 53:3-11.
5. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-7279.
6. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4:307-320.
7. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002; 94:1091-1099.
8. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22:2594-2601.
9. Danford AJ, Wang D, Wang Q, Tullius TD, Lippard SJ. Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proc Natl Acad Sci U S A 2005; 102:12311-12316.
10. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005; 107:155-176.
11. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001; 478:23-43.
12. Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 2005; 92:1149-1158.
13. Brabec V, Kasparkova J. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 2005; 8:131-146.
14. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005; 31:90-105.
15. Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004; 30:53-81.
16. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41:101-121.
17. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001; 1:99-108.
18. Chang IY, Kim MH, Kim HB, Lee do Y, Kim SH, Kim HY, et al. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005; 327:225-233.
19. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 2002; 30:3848-3856.
20. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63:1311-1316.
21. Pander J, Gelderblom H, Guchelaar HJ. Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. Expert Opin Pharmacother 2007; 8:1197-1210.
22. Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006; 24:4333-4339.
23. Duan S, Bleibel WK, Huang RS, Shukla SJ, Wu X, Badner JA, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 2007; 67:5425-5433.
24. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998; 62:1198-1211.
25. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin-rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 2002; 30:97-101.
26. Abecasis GR, Cardon LR, Cookson WO. A general test of association for quantitative traits in nuclear families. Am J Hum Genet 2000; 66:279-292.
27. Benjamini Y, Yekutieli D. Quantitative trait loci analysis using the false discovery rate. Genetics 2005; 171:783-790.
28. Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH Jr, et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 2004; 64:4353-4356.
29. Masquelier M, Zhou QF, Gruber A, Vitols S. Relationship between daunorubicin concentration and apoptosis induction in leukemic cells. Biochem Pharmacol 2004; 67:1047-1056.
30. Mansilla S, Pina B, Portugal J. Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis. Biochem J 2003; 372:703-711.
31. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005; 31:603-617.
32. Wang J, Pabla N, Wang CY, Wang W, Schoenlein PV, Dong Z. Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53. Am J Physiol Renal Physiol 2006; 291:F1300-F1307.
33. Fishel ML, Newell DR, Griffin RJ, Davison R, Wang LZ, Curtin NJ, et al. Effect of cell cycle inhibition on cisplatin-induced cytotoxicity. J Pharmacol Exp Ther 2005; 312:206-213.
34. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59:657-663.
35. Lau AH. Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int 1999; 56:1295-1298.
36. Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996; 270:F700-F708.
37. Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, Tasaka K. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol 2000; 45:199-206.
38. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A 2007; 104:9758-9763.
39. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007; 81:427-437.
40. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT. Mapping determinants of human gene expression by regional and genomewide association. Nature 2005; 437:1365-1369.
41. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS, et al. Genetic analysis of genome-wide variation in human gene expression. Nature 2004; 430:743-747.
42. Lewis AD, Hayes JD, Wolf CR. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis 1988; 9:1283-1287.
43. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24:331-344.
44. Sarries C, Haura EB, Roig B, Taron M, Abad A, Scagliotti G, et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 2002; 3:763-780.
45. Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, et al. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 2005; 11:1237-1246.
46. Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005; 11:1534-1538.
47. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001; 61:4556-4560.
48. Sato M, Mori Y, Sakurada A, Fujimura S, Horii A. The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet 1998; 103:96-101.
49. Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI, Shridhar V. Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol 1999; 15:715-720.
50. Ogama Y, Ouchida M, Yoshino T, Ito S, Takimoto H, Shiote Y, et al. Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas. Int J Oncol 2004; 25:685-691.
51. Thornborrow EC, Patel S, Mastropietro AE, Schwartzfarb EM, Manfredi JJ. qA conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene 2002; 21:990-999.
52. Dermitzakis ET, Reymond A, Scamuffa N, Ucla C, Kirkness E, Rossier C, et al. Evolutionary discrimination of mammalian conserved non-genic sequences (CNGs). Science 2003; 302:1033-1035.